Leerink Partnrs Has Optimistic Outlook of INSP Q3 Earnings

Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) - Equities researchers at Leerink Partnrs increased their Q3 2025 earnings per share (EPS) estimates for shares of Inspire Medical Systems in a note issued to investors on Monday, May 5th. Leerink Partnrs analyst M. Kratky now anticipates that the company will earn $0.72 per share for the quarter, up from their previous estimate of $0.60. The consensus estimate for Inspire Medical Systems' current full-year earnings is $2.16 per share. Leerink Partnrs also issued estimates for Inspire Medical Systems' FY2025 earnings at $2.26 EPS, FY2027 earnings at $4.29 EPS, FY2028 earnings at $5.58 EPS and FY2029 earnings at $6.69 EPS.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.33. The firm had revenue of $201.32 million for the quarter, compared to analysts' expectations of $194.89 million. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. The business's revenue was up 22.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.34) earnings per share.

Other research analysts also recently issued reports about the company. Robert W. Baird boosted their target price on Inspire Medical Systems from $230.00 to $236.00 and gave the stock an "outperform" rating in a report on Tuesday. Wells Fargo & Company reduced their price objective on Inspire Medical Systems from $195.00 to $174.00 and set an "equal weight" rating on the stock in a research note on Tuesday. KeyCorp lowered their target price on Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating for the company in a research note on Monday, April 21st. Royal Bank of Canada reduced their price target on shares of Inspire Medical Systems from $260.00 to $215.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 15th. Finally, Stifel Nicolaus lowered their price objective on shares of Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating for the company in a research report on Monday, April 21st. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, Inspire Medical Systems presently has a consensus rating of "Moderate Buy" and an average target price of $211.91.

Inspire Medical Systems Stock Up 2.0 %

NYSE:INSP opened at $161.93 on Wednesday. The firm has a market cap of $4.82 billion, a PE ratio of 93.60, a price-to-earnings-growth ratio of 2.86 and a beta of 1.39. Inspire Medical Systems has a 12 month low of $123.00 and a 12 month high of $256.11. The company's 50-day moving average price is $159.46 and its two-hundred day moving average price is $179.13.

Insiders Place Their Bets

In other news, Director Shawn Mccormick sold 360 shares of Inspire Medical Systems stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $160.00, for a total transaction of $57,600.00. Following the transaction, the director now owns 24,046 shares in the company, valued at $3,847,360. The trade was a 1.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Randy Ban sold 25,584 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the sale, the insider now owns 7,259 shares in the company, valued at approximately $1,332,026.50. The trade was a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,527 shares of company stock worth $4,851,660. Insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Mutual of America Capital Management LLC increased its position in shares of Inspire Medical Systems by 1.2% in the fourth quarter. Mutual of America Capital Management LLC now owns 4,540 shares of the company's stock valued at $842,000 after acquiring an additional 55 shares during the last quarter. True Wealth Design LLC grew its stake in Inspire Medical Systems by 39.0% in the fourth quarter. True Wealth Design LLC now owns 196 shares of the company's stock valued at $36,000 after purchasing an additional 55 shares in the last quarter. Captrust Financial Advisors increased its position in shares of Inspire Medical Systems by 2.0% during the 4th quarter. Captrust Financial Advisors now owns 3,034 shares of the company's stock worth $562,000 after purchasing an additional 59 shares during the last quarter. MML Investors Services LLC raised its stake in shares of Inspire Medical Systems by 0.9% during the 4th quarter. MML Investors Services LLC now owns 7,941 shares of the company's stock worth $1,472,000 after purchasing an additional 67 shares in the last quarter. Finally, Mariner LLC boosted its holdings in shares of Inspire Medical Systems by 1.6% in the 4th quarter. Mariner LLC now owns 4,837 shares of the company's stock valued at $897,000 after buying an additional 77 shares during the last quarter. Institutional investors own 94.91% of the company's stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.